All In Biotech

NDA 018044 · Esjay Pharma

Rocaltrol

Calcitriol · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Feb 22, 2010 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Aug 17, 1978

Approved uses

4

Original approval plus efficacy supplements

Registered trials

162

20 Phase 3, 4 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 20, 1998 Supplement 25 · Efficacy Letter
  • Jan 22, 1986 Supplement 12 · Efficacy
  • Apr 22, 1982 Supplement 4 · Efficacy
  • Aug 17, 1978 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • ROCALTROL · CALCITRIOL 0.5MCG · CAPSULE, ORAL · Prescription · TE AB
  • ROCALTROL · CALCITRIOL 0.25MCG · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Calcitriol" as an intervention, any sponsor and status, largest first.

All 162 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Rocaltrol (Calcitriol)

2024 spending

$17K

Beneficiaries

38

74 claims

Per beneficiary

$457

$12.20 per unit

View as table
YearSpending
2020$43,677
2021$41,671
2022$46,389
2023$37,011
2024$17,347

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 740 on PubMed

Sponsor: Esjay Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.